Skip to main content
[Preprint]. 2023 Jul 30:2023.07.28.550976. [Version 1] doi: 10.1101/2023.07.28.550976

Fig 1. Generation of human cancer cells expressing degradable FKBP-WRN.

Fig 1.

(A) Schematics of the FKBP-WRN degron system; E3, cellular E3 ubiquitin ligase (CRBN in the case of dTAG-13). (B) Targeting strategy to achieve knock-in of FKBP-WRN at the endogenous human WRN locus. (C) Immunoblotting confirming successful knock-in of FKBP-WRN in human cancer cell lines treated or not with 0.5 μM dTAG-13 for 24 h. One of two independent experiments is shown. (D) Viability of FKBP-WRN expressing human cancer cell lines treated or not with 0.5 μM dTAG-13 for 6 days. Where indicated, shWRN expression was induced with 1 μg/mL doxycycline (DOX). Average (+/‒ S.D.) of three independent experiments is shown. (E) Immunoblotting comparing the kinetics of dTAG-induced FKBP-WRN degradation to that of shWRN-induced WRN depletion. One of two independent experiments is shown.